Adicet Bio Inc (ACET) - Total Liabilities
Based on the latest financial reports, Adicet Bio Inc (ACET) has total liabilities worth $29.32 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ACET shareholders equity momentum to track the company's year-over-year net asset growth rate.
Adicet Bio Inc - Total Liabilities Trend (2008–2025)
This chart illustrates how Adicet Bio Inc's total liabilities have evolved over time, based on quarterly financial data. See Adicet Bio Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Adicet Bio Inc Competitors by Total Liabilities
The table below lists competitors of Adicet Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Thanh Cong Textile Garment Investment Trading JSC
VN:TCM
|
Vietnam | ₫1.78 Trillion |
|
Triunfo Participações e Investimentos S.A
SA:TPIS3
|
Brazil | R$1.87 Billion |
|
Global Connections Public Company Limited
BK:GC
|
Thailand | ฿1.34 Billion |
|
GrowGeneration Corp
NASDAQ:GRWG
|
USA | $54.90 Million |
|
BQE Water Inc
V:BQE
|
Canada | CA$6.91 Million |
|
Kilitch Drugs (India) Limited
NSE:KILITCH
|
India | Rs1.34 Billion |
|
Solutions 30 SE
PA:S30
|
France | €610.30 Million |
|
Thitikorn Public Company Limited
BK:TK
|
Thailand | ฿324.01 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Adicet Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ACET market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Adicet Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Adicet Bio Inc (2008–2025)
The table below shows the annual total liabilities of Adicet Bio Inc from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $33.15 Million | -1.38% |
| 2024-12-31 | $33.61 Million | -9.46% |
| 2023-12-31 | $37.12 Million | -3.21% |
| 2022-12-31 | $38.35 Million | +7.10% |
| 2021-12-31 | $35.81 Million | -18.63% |
| 2020-12-31 | $44.01 Million | -69.00% |
| 2019-12-31 | $141.95 Million | +2375.20% |
| 2018-12-31 | $5.74 Million | +4.23% |
| 2017-12-31 | $5.50 Million | -97.67% |
| 2016-12-31 | $236.34 Million | +0.33% |
| 2015-12-31 | $235.56 Million | +0.50% |
| 2014-12-31 | $234.40 Million | +82.00% |
| 2013-12-31 | $128.79 Million | -1.89% |
| 2012-12-31 | $131.28 Million | -12.97% |
| 2011-12-31 | $150.84 Million | +63.59% |
| 2010-12-31 | $92.21 Million | +44.31% |
| 2009-12-31 | $63.90 Million | -21.92% |
| 2008-12-31 | $81.83 Million | -- |
About Adicet Bio Inc
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops … Read more